Using remote communications technology, a major cancer center was able to manage symptoms in high-risk patients initiating treatment at a regional location.
A patient education and monitoring program improved patients’ ability to manage and report adverse events related to treatment with ICIs.
Physicians noted that patients receiving best supportive care were more likely to be interested in low-intensity treatments if the risk for side effects was lower.
Using data from 108 patients, researchers designed MIPI-P, a novel scoring system for determining MCL prognosis.
Researchers presented initial results from an ongoing, phase 3, randomized study of once-weekly SVd vs twice-weekly Vd after 1 to 3 prior anti-multiple myeloma regimens.
Zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with WM compared with ibrutinib.
Researchers reported long-term follow up from the first clinical trial of anti-CD19 CAR T cells that revealed responses against lymphoma.
Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
Researchers surveyed consecutive new patients at a multidisciplinary clinic to determine smokers’ willingness to participate in a cessation program.
Pembrolizumab showed statistically significant improvement in PFS compared with brentuximab vedotin in patients with r/r cHL.
Researchers outlined a validated p-DRI for AML and ALL that successfully stratifies children undergoing allogeneic hematopoietic cell transplantation for prognostication.
All patients enrolled in the phase 3 study had metastatic CRC characterized as MSI-H/dMMR, a biomarker found in only approximately 5% of these tumors.
Controversy exists regarding whether to offer early locoregional treatment in addition to palliative therapy to patients with de novo MBC and an intact primary tumor.
The phase 3 ADAURA trial included 682 patients with EGFR-mutated NSCLC who had complete resection of the disease.
Carfilzomib plus lenalidomide and dexamethasone failed to improve outcomes compared with bortezomib plus lenalidomide and dexamethasone among patients with newly-diagnosed MM.
Adding avelumab to best supportive care following chemo in advanced UC significantly improved OS compared with best supportive care alone.
A presentation on the interim results of the phase 3 CheckMate 9LA trial revealed a new first line treatment opportunity for patients with advanced NSCLC.
This phase 2 study used a crossover design in which study medication and placebo were administered to all patients in cycles A and B of chemotherapy, respectively.
Whether a patient received NCCN guideline-concordant care seemed to depend most heavily on race and insurance status.
No systematic investigations have evaluated the publication timing of oncology drug registration trial results relative to the approval of these drugs by the FDA.